We evaluated the adverse effect of asymptomatic Helicobacterp ylori infection in children on the response to Fe supplementation. One hundred and sixtynine children aged 1-10y ears from the urban poor community underwenta[ 13 C]urea breath test for H. pylori and haematologicalt ests at admission and after 8weeks. Both H. pylori-positive and -negative children were randomly assigned to receive ferrous fumarate syrup (20 mg elemental Fe twice daily) or placebo for 8w eeks and as ingle dose of vitamin A( 33,000 m g). Admission findings were compared between H. pylori-positive and -negative children. Response to Fe was comparedb etween Fe-supplemented H. pylori-positive and -negative children. Seventy-nine per cent of the children were aged 1-5 years and half of them were boys. In eighty-five H. pylori-positive and eighty-four H. pylori-negative children, the differences in mean Hb (112 ( SD 12·6) v .1 13 ( SD 12·0) g/l), haematocrit( 34 ( SD 3·5) v .3 5( SD 3·2) %) and ferritin (23·8 v .2 1·0 m g/l) were similar. After 8w eeks of Fe supplementation, mean Hb was 5·3g/l more (95 %C I1 ·59, 9·0) and haematocrit was 1·4% more (95 %C I0 ·2, 2·6) in H. pylori-negative ( n 44) compared with H. pyloripositive ( n 42) children. Mean ferritin was similar at admission and improved in both H. pylori-positive and -negative children. Asymptomatic H. pylori infection was not associated with higher rates of anaemia or Fe deficiency in children, but had asignificant adverse effect on response to Fe therapy. However, this result is based on exploratory analysis and needs confirmation.
The prevalence of Helicobacter pylori infection is very high in children of developing countries and in many of them it occurs in early infancy (Mahalanabis et al. 1996; Bardhan, 1997; Sarker et al. 1997) . The vast majority of these children do not present with any overt symptoms and signs attributable to this infection, which is known to cause gastritis and altered gastric acid secretion (El-Omar et al. 1997; Gutierrez et al. 1997; Sarker et al. 2004) . Infection with H. pylori has been incriminated as a cause of anaemia refractory to treatment with Fe supplements (Peach et al. 1998; Annibale et al. 1999; Choe et al. 1999 Choe et al. , 2000 Choe et al. , 2003a K onno et al. 2000; Ashorn et al. 2001 ) and several case reports have shown that its eradication improves the anaemia (Choe et al. 1999 (Choe et al. , 2000 Konno et al. 2000; Ashorn et al. 2001; Sugiyama et al. 2002; Sarker et al. 2004) . Lactoferrin is known to provide Fe for H. pylori in gastric mucosa. In an elegant study Choe et al. (2003a ) s howed that adolescents with H. pyloriassociated gastritis coexisting with anaemia had very high levels of lactoferrin in the gastric mucosa, and eradication of H. pylori in them was associated with as ignificant fall of lactoferrin level in gastric mucosa along with arise in Hb concentration. The authors suggested that the phenomenon of sequestration of lactoferrin in the gastric mucosa in subjects with H. pylori gastritis and Fe-deficiency anaemia might lead to abetter understanding of the mechanism of anaemia in H. pylori gastritis. Recently Sarker et al. (2004) showed that gastric acid secretion is significantly reduced in H. pylori-infected anaemic young children and its eradication restores gastric acid secretion. Absorption of Fe from two Fe salts, namely ferrous sulfate (water-soluble) and ferrous fumarate (water-insoluble but soluble in weak acids), in asymptomatic children aged 2-5-years infected with H. pylori was, however, not significantly different from that in children free of H. pylori infection (Sarker et al. 2004) .
Fe-deficiency anaemia remains am ajor nutritional problem in developing countries, particularly in children and women of childbearing age, and is an important cause of morbidity. In India, the National Family Health Survey II conducted in 1998/99 documented that about 74 %c hildren aged between 6a nd 35 months were anaemic (Kapil, 2003) .
We hypothesized that asymptomatic H. pylori infection in children would be associated with Fe-deficiency anaemia and that its presence would also adversely affect the response to Fe supplementation of children in developing countries. To address these primary research questions we conducted exploratory and subgroup analysis within ar andomized, double-blind, placebo-controlled trial of daily Fe supplementation along with an initial single large dose of vitamin Ainchildren and evaluated the role of H. pylori infection on response to Fe supplementation by measuring Hb, haematocrit and ferritin values. Analysis comparing the response to Fe supplements in children with asymptomatic H. pylori infection and children without such infection (i.e. asubgroup in the trial) was pre-specified in the study design. We shall report separately the results of the randomized controlled trial of Fe supplementation with ferrous fumarate in underprivileged urban children in India, which was asecondary objective of the study.
Methods

Study population and sample selection
Children aged 1t o1 0y ears, of either sex, were included in the study. Additional inclusion criteria were no antibiotics during the past month, no sign/symptoms of infection, no gastrointestinal complaints such as diarrhoea, staying within areasonable distance of the clinic ( , 3km) and parents willing to give consent. Children attending the well baby clinic at the Infectious Diseases and Beliaghata General Hospital, Kolkata, India were approached for participation in the study. This is al arge general hospital run by the government where treatment is free or subsidized and serves the urban poor. The medical officer (S.M.) of the clinic invited parents of the children in order of their registration and the first two eligible ones were recruited for the day. Written consent was obtained from the parents. The recruitment took place between June 1999 and October 2000. Baseline history and clinical examination results on the children enrolled were recorded on apre-tested data collection form. These included age, sex, weight, height, mid-arm circumference and selected socio-economic indicators. The tests done at admission to the study included determinations of Hb, haematocrit, ferritin, serum Fe and total Fe-binding capacity, and a[
13 C]urea breath test to detect H. pylori infection. The blood tests were repeated after 8w eeks of intervention. The study was approved by the Ethical Review Committees of the Society for Applied Studies, Kolkata, India and the University of Alabama at Birmingham, USA.
Randomization and treatments
Am aster randomization chart was prepared using permuted blocks of random numbers of variable block length (2, 4a nd 6) by ap erson not directly involved in the conduct of the study. The sequence in which block lengths would appear was ascertained using ar andom number table. This randomization was incorporated into the serially numbered bottles of Fe syrup or placebo syrup, so that the serial numbers of as et of bottles corresponded to the patient's serial numbers. The randomization code was kept sealed centrally and was provided to the investigators only after they submitted the data sets on completion of the study. The children after recruitment received the supplement from the numbered bottles corresponding to their serial number, prior to any knowledge about whether the child was H. pyloripositive or -negative, because breath samples for the [ 13 C]urea breath test were analysed in batch mode and the results were available only after completing the treatment protocol. Children were randomly assigned to receive Fe syrup daily or ap lacebo (identical in colour, consistency and taste) for 8w eeks. In addition, all children received at the start of Fe therapy as ingle large dose (33,000 m g) of vitamin A. Subclinical vitamin A deficiency is common in this population and asingle dose of vitamin Awas given to all children at the start to improve response to Fe supplementation. Children were provided with four bottles of Fe syrup or placebo along with ap lastic measure and their mothers were instructed to administer 5mls yrup twice daily. Each ml of syrup contained 4mge lemental Fe as ferrous fumarate. Therefore, all children in the intervention group would receive ad aily dose of 40 mg elemental Fe (four times the RDA (Food and Nutition Board, National Research Council 1989) for 1-10-year-olds). Children received the first dose of the syrup at the clinic under the supervision of the health worker before being sent home with an appointment to return to the clinic after 4w eeks. At 4w eeks, parents were asked about syrup intake and side-effects if any, and as econd set of four bottles was given for the second 4w eeks with an appointment to return at 8w eeks for final evaluation.
Random allocation to two groups resulted in the following four groups: (i) H. pylori-positive children treated daily with Fe syrup; (ii) H. pylori-positive children treated daily with placebo syrup; (iii) H. pylori-negative children treated daily with Fe syrup; and (iv) H. pylori-negative children treated daily with placebo syrup.
Follow-up procedures
Children were asked to return to the clinic after 4weeks or earlier if they felt the need. If they missed the appointment at 4weeks, a home visit was made to ascertain the reason and to encourage them to come. An appointment for as econd visit at 8w eeks was given and if they failed, ahome visit was made to encourage them to return.
Sample size
For comparison between H. pylori-positive and -negative children and to detect adifference of 5g/l in Hb between the two groups at admission, seventy-five children would be needed in each group based on an expected mean Hb level of 110 g/l with SD of 11 g/l (at 80 %power and 95 %confidence). For evaluating the difference in response to Fe supplementation between H. pylori-positive and H. pylori-negative children with an expected difference in mean Hb of 8g/l, we would need forty H. pylori-positive and forty H. pylori-negative children in the Fe-supplemented group. Using aconservative estimate that 50 %would be positive for H. pylori, we would need to recruit at otal of 160 children for the subgroup analysis. We added 5% more to this figure to compensate for loss to follow-up.
Statistical considerations and data analysis
We planned to make comparisons at two levels. At enrolment, the haematological indices were compared between H. pylori-positive and -negative children. For evaluation of the role of H. pylori infection on the response to Fe supplementation, we compared the haematological indices in the Fe-supplemented H. pylori-positive children with those in the Fe-supplemented H. pylori-negative children (i.e. groups (i) and (iii)) at admission and after 8w eeks of supplementation. This subgroup would constitute about half of the children enrolled in the trial. This analysis plan was pre-specified and is reflected in the sample size calculation given above.
EpiInfo version 6.0 (Centers for Disease Control and Prevention, Atlanta, GA, USA and WHO, Geneva, Switzerland) was used for entering and editing data. To evaluate the association of H. pylori infection with Fe deficiency and/or anaemia, all children recruited into the trial were divided into two groups according to H. pylori infection status. Their baseline features were summarized and compared. Their haematological indices at admission were compared by one-way ANOVA, anon-parametric test or the x 2 test. Where relevant, use of appropriate regression models (multiple linear regression and logistic regression) was planned to adjust for covariates.
To evaluate the effect of H. pylori infection on the response to Fe we used multiple linear regression models. As afi rst step all children in the trial were included in the model and the interaction between Fe treatment and H. pylori infection was evaluated along with other explanatory and/or confounding factors. Separate models were fitted with Hb, haematocrit or ferritin values at 8w eeks after supplementation. Treatment effect was modelled with the interaction term between treatment and H. pylori status along with other baseline features such as sex and age. We then directly compared the subgroups of children with and without H. pylori infection treated with Fe supplement to evaluate the role of H. pylori infection on the treatment outcome. Regression models were used on this subgroup for evaluating treatment effect on Hb, haematocrit and ferritin with H. pylori status, sex and age as covariates. These models provided estimates for the role of H. pylori infection on the response to Fe supplementation. For regression models we used Stata version 7.0 software (Stata Corporation, College Station, TX, USA).
Laboratory analyses [
13 C]Urea breath test.T he [
13 C]urea breath test has high specificity and sensitivity and is widely accepted as an on-invasive technique for diagnosing current H. pylori infection (Logan et al. 1991; Vandenplas et al. 1991) . [
13 C]Urea is degraded rapidly in the presence of H. pylori urease to 13 CO 2 and NH 3 , and the former is excreted in the breath. Ab aseline breath sample was collected. The child then drank about 100 ml milk, followed by at est dose of [ 13 C]urea (99 %[ 13 C]urea; Sigma, St. Louis, MO, USA) at ad ose of 30 mg for children less than 24 months old and 40 mg for children older than 24 months, dissolved in 50 ml sterile water. After 30 min the second breath sample was collected. Older children who were able to cooperate were asked to blow air through at ube into ap lastic bag with an attached needle. Vacutainer tubes were filled using the attached needle. For younger children, not able to cooperate, af acemask with ao ne-way outlet valve was used to collect breath directly into aV acutainer tube. Samples were collected in duplicate. Breath samples were analysed for 13 Co fr espiratory CO 2 by GC -isotope ratio MS at St. John's Medical College, Bangalore, India. Breath samples with an excess over baseline enrichment of 13 C . D 5·0‰ were regarded positive for H. pylori infection. The [
13 C]urea breath test has been shown to be 100 %s ensitive and 92 %s pecific and is considered ar eference standard for the diagnosis of H. pylori infection in children (Rowland et al. 1997) .
Haematological tests.V enous blood samples (2·5 ml) were drawn; 0·5mlw as taken into an EDTA-treated tube and analysed for Hb using the cyanmethaemoglobin (colorimetric) method (Randox w kit; Randox Laboratories, San Diego, CA, USA) and the remaining 2mlw as taken into ap lain tube and treated to obtain serum. Serum Fe and total Fe-binding capacity were determined using ac olorimetric method (Randox w kit; Randox Laboratories). For ferritin, as olid-phase immunoradiometric assay based on monoclonal and polyclonal anti-ferritin antibodies was used (Coat-A-Count Ferritin IRMA kit; Diagnostics Products Corporation, Los Angeles, CA, USA). The radioactivity is measured using ag amma counter and the concentration of ferritin is obtained by comparing the counts per minute with those obtained for the set of calibrators provided. The calibrators contain ferritin in terms of the WHO Second International Reference Preparation of Ferritin for Immunoassay, number 80/578 (2nd IS 80/578).
Results
Twohundred andforty-one children were assessed foreligibility and 176c hildrenw erer ecruited in thes tudy ( Fig .1 ) ( Table 1) .T he twog roupsw eres imilar in termso fa ge,s ex anda nthropometrici ndicatorss ucha sw eightfor-age, weight-for-heighta nd height-for-age SD scores compared with theN ationalC enterf or Health Statistics (Dibley et al. 1987) referencedata, andmid-arm circumference. Theproportionofilliteratemothers wasmarginallyhigherinthe H. pylori-positivechildren.
Haematological indices for H. pylori-positive and -negative children at admission are compared in Table 2 . Mean Hb, haematocrit, serum Fe, total and unsaturated Fe-binding capacity, the proportions with low ( , 12 m g/l) serum ferritin and the geometric mean serum ferritin concentrations were not significantly different between the two groups. About 40 %o ft he children were anaemic as defined by Hb , 110 g/l.
Eighty-three children were randomized to the placebo group, of whom forty-three were positive and forty negative for H. pylori. Haematological indices at admission and after 8w eeks of supplementation with placebo were similar between the H. pylori-positive and -negative groups, and between admission and 8-week values in each group (data not shown).
In three separate regression models on all children in the trial we evaluated the effect of the interaction between H. pylori infection and Fe treatment on Hb concentration, haematocrit and ferritin after 8w eeks of supplementation ( Table 3) . At rend for a negative interaction was noted for Hb concentration ( 2 4·5; 95 %C I2 ·15, 2 11·15) and haematocrit ( 2 1·2; 95 %C I0 ·73, 2 3·13). Ap ositive interaction was seen for ferritin concentration (ratio of geometric means ¼ 1·67; 95 %C I1 ·02, 2·75).
Among the Fe-supplemented subgroup, forty-two children were positive and forty-four were negative for H. pylori.H aematological indices at admission and after 8weeks of supplementation are shown in Table 4 . Two in the H. pylori-negative group defaulted at the final evaluation at 8w eeks. Eight children (five in the H. pylori-positive and three in the H. pylori-negative group) did not receive Fe syrup for the second 4w eeks but returned for final evaluation at 8w eeks. These eight children were included in the analysis. Upon daily Fe supplementation the children with H. pylori infection had no significant increase in mean blood Hb concentration, whereas the H. pylori-negative children had as ignificant rise, with am ean increase in Hb of 5·3g/l (95 %C I1 ·59, 9·00; P # 0·001) compared with baseline values. Similarly, the H. pylori-negative children had as ignificant rise in haematocrit values after Fe supplementation compared with admission values of 1·34 %(95 %CI0 ·07, 2·62), but there was no significant increase in the H. pylori-positive children. After 8w eeks of Fe supplementation the proportion of children with Hb , 110 g/l was nearly double in the H. pylori-positive children compared with the H. pylori-negative ones (relative risk ¼ 1·9; 95 %C I1 ·04, 3·48; P ¼ 0·029). Furthermore, after 8w eeks of Fe supplementation, Hb and haematocrit values were higher in the H. pylori-negative children than in -positive ones (Table 4) . There was no significant difference in serum ferritin values between the two groups after Fe supplementation. However, Fe supplementation resulted in as ignificant fall in the proportion of children with serum ferritin , 12 m g/l in both groups compared with admission values. Moreover, the proportion with low ferritin levels (i.e. , 12 m g/l) was substantially reduced as aw hole after Fe supplementation (i.e. in H. pylori-positive and -negative children taken together) compared with the two placebo groups combined (relative risk ¼ 15; 95 %C I2 ,6 53; P ¼ 0·002; data not shown). Using regression models on all children in the trial we could also show that the geometric mean ferritin level after 8w eeks of supplementation was 54 %h igher in the Fe-supplemented group than in the placebo group (ratio of geometric means ¼ 1·54; 95 %C I1 ·20, 1·97; P ¼ 0·001). There was a trend for total ( P ¼ 0·076) and unsaturated ( P ¼ 0·087) Fe-binding capacity to be higher in H. pylori-positive children after Fe supplementation compared with H. pylori-negative ones. No significant difference was noted in serum Fe values either at admission or after Fe supplementation. We used separate regression models with Hb and haematocrit as dependent variables and H. pylori infection along with admission value of Hb or haematocrit as independent variable to estimate the adverse effect of H. pylori infection in the subgroup of children who received Fe supplements (data not shown). The results were closely similar to unadjusted analyses (Table 4) . The presence of H. pylori infection was associated with ar eduction of 5·27 g/l in Hb (95 %C I1 ·31, None of the differences between the two groups were significant (ANOVA or x 2 test). Analysis adjusted for sex and age showed no significant difference between the two groups (regression models). 
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*Separate multiple linear regression models were fitted for Hb, haematocrit and ferritin values after 8w eeks of supplementation (dependent variables) on all children in the trial. Other variables in the models are treatment with Fe, H. pylori status, sex, age and admission values of Hb or haematocrit or ferritin (log-transformed). †Ferritin was modelled after log transformation and therefore the effect and confidence interval are in ratio mode. ‡ H. pylori:present¼ 1, absent ¼ 0; treatment with Fe: yes ¼ 1, no ¼ 0. ·28, 59·32 ). ** RR=0.55, (95% CI 0.30 to 1.00, P =0.041) Differences among the groups at admission were not significant at the 5% level.
9·23
) and ar eduction of 1·34 %i nh aematocrit (95 %C I0 ·07, 2·62). H. pylori infection was associated with an on-significant increase in serum ferritin of 20 %( 95 %C I 2 17, 72).
Among children who received the placebo, forty-three were positive and forty were negative for H. pylori by the [ 13 C]urea breath test. Hb, haematocrit and serum ferritin values at 8 weeks were not significantly different from the admission values (data not shown). Likewise, serum Fe, total and unsaturated Fe-binding capacities at 8weeks were also similar to admission values in both groups.
